IFNG and neoplasm: DCVax-L will potentially initiate the polyclonal T cell response, indirectly boost NK cell function (by cross-activation via cytokines like IFN-γ), and obtain a broad-spectrum anti-tumor immunity, hailing new hope for glioblastoma treatment.